ArticleDermatology and therapy2026
Epidemiology and Treatment Patterns of Stage III Resectable Melanoma Treated with Adjuvant Therapy: A Real-World Study Using the SNDS Database in France.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBefore the advent of neoadjuvant immunotherapy (IO) in macroscopic disease, IO and targeted therapies were recommended as adjuvant therapies for the treatment of stage III resectable melanoma. However, real-world evidence on their use and outcomes remains limited. This study described treatment patterns and survival outcomes among patients with stage III resectable melanoma who received adjuvant therapy in France.
methodsThis retrospective cohort study used data from the exhaustive French national health data system (SNDS) to identify adults initiating adjuvant nivolumab (NIVO), pembrolizumab (PEM), or dabrafenib-trametinib (DT) between January 1, 2019, and December 31, 2021. Patients were followed until December 31, 2023, or death. Exclusion criteria included prior metastatic disease, other active cancers, or prior use of study drugs. Outcomes included treatment patterns at recurrence, described using Sankey diagrams, and survival (recurrence-free survival [RFS], overall survival [OS]), assessed using a Kaplan-Meier estimator.
resultsThe study population consisted of 2612 patients with resected stage III melanoma initiating an adjuvant therapy. Of them, 1483 (56.8%) received NIVO, 635 (24.3%) had PEM, and 494 (18.9%) had DT. Median (Q1-Q3) age was 64.0 (52.0-73.0) years for NIVO, 64.0 (51.0-74.0) years for PEM, and 58.0 (46.0-70.0) years for DT. Median follow-up was 39.5 months for NIVO, 38.9 months for PEM, and 36.9 for DT. At 36 months, RFS (95% CI) was 50.7% (48.0%-53.2%) for NIVO, 52.7% (48.6-56.7%) for PEM, and 48.3% (43.7-52.7%) for DT. Finally, 36-month OS (95% CI) was 81.8% (79.7-83.8%) for NIVO, 82.3% (79.0-85.2%) for PEM, and 74.4% (70.1-78.2%) for DT. Immunotherapy represented 75% of therapies at recurrence among patients with adjuvant NIVO/PEM and 55% among patients with adjuvant DT.
conclusionImmunotherapy is the cornerstone of adjuvant and recurrence treatment in stage III melanoma, representing the vast majority of adjuvant therapies and recurrence therapies. Despite effective therapies, recurrence remains frequent, with around half of relapses at 3 years, underscoring the need for continued optimization of treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.